Premier Alternatives

Signatur Biosciences

Thame, United Kingdom · Founded 2022 · Privately Held (backing)

Developer of a PCR testing platform designed to make precision diagnostics accessible to all. Signatur Biosciences is based in Thame, United Kingdom and was founded in 2022. Its last reported valuation was $7.1 million in Jan 2022. It has raised $7.5 million.

Last reported valuation
$7.1M
Oct 2026
Priced at
—
Total raised
$7.5M
Last round
—

Signatur Biosciences key facts

as of Oct 2026
  • Developer of a PCR testing platform designed to make precision diagnostics accessible to all.
  • Signatur Biosciences is valued at approximately $7.1M as of Oct 2026 (last reported valuation).
  • It has raised $7.5M; the latest was Seed Round ($7.0M) in May 2025.
  • Notable investors include Y Combinator, Imperial Enterprise Lab, Noshaq, Anjost Investment, PSR Crypto — 8 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$7.1M

Signatur Biosciences's last reported valuation, Jan 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Private Market View
More of Signatur Biosciences with a free Private Market View account
  • ·Watch Signatur Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Signatur Biosciences funding rounds

No rounds on record

No funding rounds for Signatur Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Signatur Biosciences valuation

Signatur Biosciences's last reported valuation was $7.1 million in Jan 2022. No priced round, secondary trade or fund mark has surfaced since.

Signatur Biosciences investors

8 investors are on record for Signatur Biosciences, including Y Combinator, Imperial Enterprise Lab, Noshaq and Anjost Investment.

About Signatur Biosciences

Developer of a PCR testing platform designed to make precision diagnostics accessible to all. The company's technology uses the molecular machinery of PCR to condense all the work of detecting and interpreting a panel of RNA biomarkers into a single test, and offers a smart kit compatible with existing machines and off-the-shelf reagents, enabling clinicians to integrate with existing clinical workflows and infrastructure.

Sector
Healthcare
HQ
Thame, United Kingdom
Founded
2022
Employees
9
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.